UK experience of ofatumumab in recurrence of focal segmental glomerulosclerosis post-kidney transplant.

OFA may represent a useful addition to therapeutic options in the management of FSGS recurrence post-transplantation, including where RTX has shown no benefit. Concomitant plasmapheresis in all patients prevents any definitive conclusion that OFA was the beneficial intervention.